Novo Nordisk, the company behind Ozempic and Wegovy, published a new analysis of the longest study it has conducted so far through the lens of long-term weight loss.
The 17,604-person study, published in Nature Medicine and presented at the European Congress on Obesity in Venice, Italy on Tuesday, showed for the first time that obesity patients without diabetes maintained a 10% average weight loss over four years after taking Wegovy.
“We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug,” Martin Holst Lange, Novo’s development head, told Reuters in an interview.
The findings
→ Continue reading at Entrepreneur